Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m

Executive Summary

WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.

Advertisement

Related Content

Time Is Of The Essence As Teva Considers European Assets Bids
Mundipharma Acquires 'Smart' Chemo Drug From CellAct
Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
HitGen Hits China Drug Discovery Jackpot With MNC Tie-ups
Tackling Acute Gastroenteritis: RedHill Biopharma's Bekinda A Novel Approach?
Pipeline Watch: Top-Line Phase III Brexpiprazole, Ferumoxytol Results
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
VC Roundup: Moderna Seeks Another Record-Breaking Raise; Arcus Emerges From Stealth Mode
SAD, BAD Or DAD? Insiders See Risks Increasing In China IO Rush
FINANCE ROUNDUP: Three IPOs and three VC rounds

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel